Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Packaged food manufacturers and fast-food restaurants are preparing for major shifts in consumer demand as appetite-suppressing GLP-1 weight loss pills are expected to enter the U.S. market in early 2025. Analysts believe these oral medications could accelerate long-term changes in eating habits, forcing food companies to reformulate products, adjust portion sizes, and emphasize nutrition-focused offerings.
The U.S. Food and Drug Administration recently approved Novo Nordisk’s Wegovy GLP-1 pill, a milestone that sent shares of several food companies lower. Unlike injectable GLP-1 drugs, the pill form is expected to be cheaper and more appealing to patients who are uncomfortable with injections. Eli Lilly’s competing GLP-1 pill is also anticipated to receive regulatory approval next year, further expanding access to weight loss medications.
As adoption grows, analysts say Americans are likely to reduce consumption of calorie-dense foods such as salty snacks, baked goods, soda, alcohol, and sugary drinks. Instead, demand is shifting toward high-protein, high-fiber, and functional foods that support satiety and portion control. This trend has already been visible with injectable GLP-1 drugs and is expected to intensify with easier-to-use pills.
Research supports this shift. A recent Cornell University study found that households using GLP-1 medications reduced grocery spending by over 5% and fast-food spending by about 8%. While spending rebounded after discontinuing the drugs, experts believe lower-cost pills could encourage longer-term use, broadening the impact across the food industry.
Major companies are responding quickly. Conagra Brands has begun labeling certain Healthy Choice meals as “GLP-1 friendly,” citing faster sales than competing products. Danone reports double-digit growth in high-protein yogurt, while Nestlé has launched new frozen meals tailored to GLP-1 users. Restaurants are also adapting, with chains like Chipotle introducing high-protein menu options and others offering smaller, lower-priced portions.
With nearly 40% of U.S. adults classified as obese and growing interest in weight loss solutions, GLP-1 pills are poised to reshape how Americans eat—and how food companies innovate—for years to come.
